Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Besson

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|August 31, 2019
In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort studyLaure Philippe, Remi Lancar, Camille Laurent, et al.
Eclinicalmedicine|October 19, 2020
Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort studySylvain Lamure, Rémy Duléry, Roberta Di Blasi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR CohortCaroline Besson, Remi Lancar, Sophie Prevot, et al.
Leukemia|February 2, 2022
Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysisThomas Hueso, Anne-Sophie Godron, Emilie Lanoy, et al.
The Lancet. Haematology|August 2, 2023
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trialPaul G Rubinstein, Page C Moore, Milan Bimali, et al.
AIDS (London, England)|September 20, 2017
Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy eraCaroline Besson, Remi Lancar, Sophie Prevot, et al.
Plos One|June 4, 2016
In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin LymphomasDanielle Canioni, Jean-Marie Michot, Pascaline Rabiega, et al.
American Journal of Hematology|April 28, 2021
Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapyRémy Duléry, Sylvain Lamure, Marc Delord, et al.
Cancer|September 25, 2014
Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective studyJorge J Castillo, Mark Bower, Jérémy Brühlmann, et al.
AIDS (London, England)|December 14, 2019
Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIVCaroline Besson, Nicolas Noel, Remi Lancar, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|August 31, 2019
In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort studyLaure Philippe, Remi Lancar, Camille Laurent, et al.
Eclinicalmedicine|October 19, 2020
Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort studySylvain Lamure, Rémy Duléry, Roberta Di Blasi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR CohortCaroline Besson, Remi Lancar, Sophie Prevot, et al.
Leukemia|February 2, 2022
Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysisThomas Hueso, Anne-Sophie Godron, Emilie Lanoy, et al.
The Lancet. Haematology|August 2, 2023
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trialPaul G Rubinstein, Page C Moore, Milan Bimali, et al.
AIDS (London, England)|September 20, 2017
Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy eraCaroline Besson, Remi Lancar, Sophie Prevot, et al.
Plos One|June 4, 2016
In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin LymphomasDanielle Canioni, Jean-Marie Michot, Pascaline Rabiega, et al.
American Journal of Hematology|April 28, 2021
Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapyRémy Duléry, Sylvain Lamure, Marc Delord, et al.
Cancer|September 25, 2014
Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective studyJorge J Castillo, Mark Bower, Jérémy Brühlmann, et al.
AIDS (London, England)|December 14, 2019
Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIVCaroline Besson, Nicolas Noel, Remi Lancar, et al.
Pageof 10